Tumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A lingitudinal study

Abstract

Eighty‐two patients diagnosed with gastrointestinal (GI) adenocarcinoma were evaluated before and for 26 months after primary tumor resection for the presence of two serum tumor markers: tumor‐associated glycoprotein‐72 (TAG‐72) and carcinoembryonic antigen (CEA). Elevated TAG‐72 and CEA serum levels were found preoperatively in 32 (39%) and 34 (41.5%) of the 82 patients, respectively. The percentage of patients with elevated serum levels of either TAG‐72 or CEA was 56.1% (46 of 82). Twelve (15%) patients who had normal CEA serum levels had elevated TAG‐72 serum levels, and conversely, serum from 14 (17%) patients who were TAG‐72 negative were CEA positive. Forty‐five of the 82 patients were diagnosed with advanced disease (i.e., Stages C and D for colorectal, Stages III and IV for stomach), and 29 (64.4%) and 26 (57.8%) of those patients had elevated serum levels of TAG‐72 or CEA, respectively. Elevated levels of either TAG‐72 or CEA, however, were found in sera of 82.2% of patients with advanced GI cancer, which is an increase of 24.4% over the use of CEA antigen alone as a marker of disease. The measurement of both TAG‐72 and CEA may improve the diagnosis of patients with GI malignant disease due to the apparent complementary association which exists between these tumor markers. Serum TAG‐72 and CEA levels were monitored in 31 patients for varying lengths of time after resection of the carcinoma; 11 patients developed recurrent disease. Sera from nine of 11 (81.8%) of these patients had elevated TAG‐72 levels and six of 11 (54.5%) had elevated CEA levels. Tumor marker elevations were observed either before (35 to 166 days) or at the time of diagnosis of recurrence. The elevation of one or both markers correlated with the clinical status in ten of 11 (90.9%) patients with recurrence. In addition, 20 patients who were clinically free of disease after more than 700 days' follow‐up had normal serum levels of both TAG‐72 and CEA. These findings suggest that the combined use of serum TAG‐72 and CEA measurements may improve detection of recurrence in patients with GI cancer and may be useful in the postsurgical management of GI adenocarcinoma patients. 68:2443‐2450, 1991.

Differential Expression of a New Tumor-Associated Antigen, TLP, During Human Colorectal Cancer Tumorigenesis

“…Some of these molecules are not only expressed at the tissue level, but also shed into the biological fluids. 1,[7][8][9][10][11][12][13] Among those, TLP has been suggested to be a potential new tumor antigen. In fact, a recent report by Garaci et al 17 demonstrated that the TLP antigen was present in sera of patients diagnosed with a variety of malignant diseases, including lung and colorectal carcinoma.…”

“…[1][2][3][4][5][6] Moreover, extensive studies have shown the clinical utility of the measurement of serum expression of these antigens as an additional diagnostic parameter for early diagnosis of recurrent disease during postsurgical follow-up. 1,[7][8][9][10][11][12][13] In the past 15 years, several new tumor-associated antigens have been identified and characterized. Among those, tumor liberated particles, also referred as tumor liberated protein (TLP) by other authors have recently been proposed as a new tumor-associated antigen.…”

Mucin-associated sialosyl-Tn antigen expression in gastric cancer correlates with an adverse outcome

“…STn has been detected at abnormally high levels in the serum of 28-59% of gastric cancer patients (Farinati et al, 1989;Heptner et al, 1989;Correale et al, 1991;Guadagni et al, 1991Guadagni et al, , 1992Motoo et al, 1991), and in this disease STn (defined as CA72-4 antigen) is a more sensitive and specific marker than either carcinoembryonic antigen or CA19-9 (Heptner, et al, 1989;Guadagni et al, 1992). Moreover, elevated circulating STn levels may predict the development of recurrent gastric cancer after surgical resection more accurately than CEA (Guadagni et al, 1991(Guadagni et al, , 1992. It seems, however, that only late-stage gastric carcinomas are associated with elevated serum STn levels (Guadagni et al, 1991(Guadagni et al, , 1992.…”

“…Moreover, elevated circulating STn levels may predict the development of recurrent gastric cancer after surgical resection more accurately than CEA (Guadagni et al, 1991(Guadagni et al, , 1992. It seems, however, that only late-stage gastric carcinomas are associated with elevated serum STn levels (Guadagni et al, 1991(Guadagni et al, , 1992. It is not yet clear why patients with STn-positive tumours should have a worse prognosis than those with STn-negative tumours.…”

Effect of the Multiple Intravenous Administration of Cultured Human Autologous Adipose-Derived Stem Cells on Tumor Biomarker Levels

“…This glycoprotein is detectable in the body fluids of cancer patients and was used as a marker for the diagnosis of malignant tumors in the gastrointestinal tract [24,25]. It is produced in both normal tissues and tumors in the digestive tract and is frequently used as a marker for various malignant diseases including those of the colon, stomach, and pancreas.…”